Panref

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Panref

Quick Facts

Property Description
Active ingredient Pantoprazole
Form Delayed-release tablet (Enteric-coated), Intravenous formulation
Pharmacological class Proton Pump Inhibitor (PPI)
General purpose Sustained reduction of stomach acid
Origin Synthetic, substituted benzimidazole

What Type of Medicine is Panref (Pantoprazole)?

Panref is a prescription-only pharmaceutical product that contains the active substance Pantoprazole, which is classified as a Proton Pump Inhibitor (PPI). This single-ingredient medicine belongs chemically to the substituted benzimidazole group. Its core function is rooted in its highly specific action as a potent antisecretory agent.

The medication is synthetic in origin and is characterized by its ability to directly and profoundly suppress the stomach's capacity for acid production. Pantoprazole works by blocking the acid-producing pumps in the gastric lining. This specific action provides the benefit of effectively and consistently managing the amount of acid present in the digestive system, a general purpose commonly associated with controlling chronic acid issues.

Composition and Purpose: A Targeted Approach to Acid Control

The active ingredient, Pantoprazole (typically as the sodium sesquihydrate salt), is most frequently supplied as an enteric-coated tablet, a highly specialized oral dosage form. This design is a critical, distinguishing factor for oral administration, as the Pantoprazole molecule is inherently sensitive and susceptible to rapid degradation from stomach acid.

This crucial delayed-release coating allows the drug to pass intact into the stomach and into the small intestine, where it can be absorbed effectively into the bloodstream. This specialized coating is essential for the drug to work correctly, as it ensures the necessary quantity reaches the gastric parietal cells to deliver its final function: a consistent, profound reduction in stomach acidity to relieve associated discomfort and support the healing of the digestive lining.

What side effects are possible with Panref?

Possible side effects and safety information

The possible side effects and safety profile of Panref (pantoprazole) are officially categorized by regulatory authorities, reflecting data gathered from clinical trials and post-marketing surveillance. Adverse reactions are grouped by the body system affected and their reported frequency, as defined in official prescribing information.

Commonly Documented Adverse Reactions

The most frequently reported adverse reactions, classified as common (ge 1/100 to < 1/10), include disorders related to the gastrointestinal system and nervous system. These typically involve headache, diarrhea, abdominal pain, flatulence, nausea, and vomiting [NIH MedlinePlus]. Uncommon reactions include dizziness, insomnia, and rash.

Serious Adverse Reactions and Regulatory Constraints

The regulatory label documents specific, clinically significant reactions classified as rare or very rare. These include severe cutaneous reactions, such as Stevens-Johnson Syndrome, and acute interstitial nephritis, which can occur at any time during therapy. The medicine is contraindicated in individuals with known hypersensitivity to pantoprazole or related substituted benzimidazoles [FDA Prescribing Information].

Duration- and Population-Related Safety Notes

Safety statements in regulatory documents explicitly address risks associated with the duration of exposure. Long-term use (generally one year or more) has been associated with an increased risk of bone fracture of the hip, wrist, or spine. Additionally, prolonged treatment (at least three months) is associated with the potential for hypomagnesemia, an electrolyte imbalance [EMA SmPC]. Use of the drug may also potentially mask the symptoms of underlying gastric malignancy.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory information describes overdose primarily through the resulting clinical manifestations and the required immediate emergency response.

Any ingestion of Panref that exceeds the prescribed dose should be treated as a medical emergency.

Documented Overdose Symptoms

The most commonly documented clinical manifestations associated with an overdose of Panref, as reported in regulatory materials, involve the gastrointestinal system. These acute symptoms may include:

  • Nausea
  • Vomiting
  • Diarrhea

Immediate Emergency Action Required

Any use of Panref exceeding the prescribed dose should prompt immediate action. Do not wait for symptoms to worsen.

Situation
If an overdose is suspected Contact a poison control center immediately.
Seeking medical assistance Get medical help immediately.

In addition to the acute symptoms of over-ingestion, immediate emergency treatment is required for signs of rare, life-threatening severe allergic or hypersensitivity reactions associated with the medication (such as Stevens-Johnson syndrome or Toxic Epidermal Necrolysis). These severe reactions require immediate emergency treatment and permanent discontinuation of Panref.

Therapeutic Uses of Panref

Quick Facts: Uses of Panref

  • Helps manage erosive esophagitis associated with Gastroesophageal Reflux Disease (GERD).
  • Assists in maintaining the healing of erosive esophagitis following initial treatment.
  • An option for the management of pathological hypersecretory conditions, including Zollinger-Ellison Syndrome.

Panref is a medication used in the management of specific conditions related to excess stomach acid. The medication is indicated for the short-term treatment of erosive esophagitis, which involves injury to the lining of the esophagus due to acid reflux. In this context, Panref may help support the healing process and provide symptomatic relief for associated heartburn.

Following the healing phase, Panref may also be used for the maintenance of healing of erosive esophagitis. This long-term use is intended to reduce the chance of symptoms returning in adults. Additionally, this therapy may be used for individuals dealing with pathological hypersecretory conditions, such as Zollinger-Ellison Syndrome, where the body produces too much stomach acid.

Eligibility and Restrictions for Use

Who Can and Cannot Use Panref? (Official Eligibility Profile)

Eligibility for Panref (pantoprazole) is strictly determined by official regulatory guidelines, focusing on absolute exclusions and specific population constraints.

Contraindications and Restrictions

Classification Rule
Absolute Contraindication Patients with a known hypersensitivity to pantoprazole, substituted benzimidazoles, or any component of the formulation.
Co-administration Exclusion Use is strictly forbidden with rilpivirine-containing products.
Pediatric Exclusions Safety and effectiveness are not established for children under 5 years of age.

Conditional Use Populations

Certain groups require additional caution or usage limitation based on official labeling:

  • Pregnancy and Lactation: Use during pregnancy is recommended only if clearly needed. Due to its excretion into human milk, a decision must be made to discontinue nursing or discontinue the drug.
  • Hepatic Impairment: While no dose adjustment is typically needed for liver impairment, doses higher than 40 mg/day have not been studied in patients with severe hepatic disease.
  • Prior to Use: Clinicians must preclude gastric malignancy in adult patients before initiating therapy.

This structure ensures that the medicine is only prescribed or dispensed according to established regulatory parameters, defining those who are eligible, restricted, or excluded from treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Panref (Pantoprazole) is subject to officially documented interaction patterns primarily through its profound acid-suppressing effect and its metabolism via the CYP2C19 enzyme.

Interaction-Related Restrictions

The co-administration of Panref is formally contraindicated with Rilpivirine-containing products and Atazanavir, as stated in regulatory labels. This is due to the risk of a significant pharmacokinetic reduction in the plasma concentration of the antivirals, which may lead to a loss of therapeutic effect.

Exposure-Modifying and Pharmacodynamic Interactions

Panref may alter the systemic exposure of several other medicines, requiring specific monitoring. Co-administration, particularly at high doses, may elevate and prolong serum levels of Methotrexate and its metabolite. Conversely, the official labeling notes a reduction in the exposure of the active metabolite of the antiplatelet medicine Clopidogrel.

Additionally, Panref's acid suppression may reduce the absorption of medicines whose bioavailability is dependent on gastric pH for dissolution, such as the antifungals Ketoconazole and Itraconazole, and the tyrosine kinase inhibitor Erlotinib. Concomitant use with Warfarin or other coumarin anticoagulants may result in an increase in the International Normalized Ratio (INR).

Food intake may delay the drug's absorption but does not alter the overall extent of exposure (AUC), according to regulatory documentation. No mandatory time-separation rules are explicitly required for the oral formulation.

Mechanism of Action

How Panref Works: Mechanism of Action

Panref functions as a prodrug that undergoes activation in the acidic environment of the stomach's parietal cells. The activated compound acts as an irreversible inhibitor of the H^+/ K^+- ATPase (Proton Pump), the enzyme responsible for the final step of gastric acid secretion. By forming a permanent covalent bond with this enzyme, Panref effectively shuts down the exchange of hydrogen ions for potassium ions, thus blocking the release of acid into the stomach lumen.

This molecular interaction causes a long-lasting reduction in acid output, modulating both basal and stimulated acid secretion. The physiological consequence of this sustained inhibition is the establishment of an environment of reduced acidity within the stomach, which defines the drug's core pharmacodynamic action and leads to its extended duration of biological effect.

Dosage and Administration Information

How to Use Panref (Pantoprazole Sodium) — Administration Guidelines

The following instructions detail the use, dosage, and administration of Panref.


Dosage Forms and Approved Routes

Panref is available in Delayed-Release Tablets, Delayed-Release Granules for Oral Suspension, and Powder for Injection.

Dosage Form Approved Route(s) Administration Timing
Delayed-Release Tablet Oral Can be taken with or without food.
Oral Suspension Granules Oral or Nasogastric (NG) Tube Approximately 30 minutes before a meal.
Powder for Injection Intravenous (IV) Infusion As directed by a healthcare professional.

Administration and Handling Requirements

To maintain the delayed-release properties of the oral formulations, specific handling rules must be followed:

  • Delayed-Release Tablets must be swallowed whole. They must not be split, crushed, or chewed.
  • Oral Suspension Granules must only be mixed with apple juice or applesauce. Do not crush or chew the granules.
  • Intravenous Injection requires reconstitution and dilution with specific solutions (e.g., 0.9% Sodium Chloride or 5% Dextrose) and must be administered over a defined time, such as 15 minutes for the 40 mg dose.

Standard Dosing and Frequency

The standard adult oral dose for the treatment of erosive esophagitis is 40 mg once daily (QD). For most uses, Panref is taken once a day. Treatment duration for short-term erosive esophagitis is typically up to 8 weeks.

Recent Clinical Evidence

Panref: Recent Clinical Evidence

Clinical evidence for the active compound in Panref, a proton pump inhibitor, primarily relates to its use in treating conditions associated with excess stomach acid. These conditions include erosive and non-erosive gastroesophageal reflux disease (GERD) and pathological hypersecretory states, such as Zollinger-Ellison syndrome.


Efficacy and Symptom Relief Studies

Numerous clinical trials have been conducted to evaluate the effects of the compound on GERD symptoms. Studies designed to assess symptom relief often use standardized questionnaires to track changes in heartburn, regurgitation, and sleep disturbance over periods typically ranging from 4 to 8 weeks. Research has generally focused on measuring the rate of symptom relief, the time taken to achieve the initial relief, and the effect on the quality of life in both erosive and non-erosive forms of the condition.


Tolerability and Comparison

Research indicates that the compound is generally well-tolerated. In clinical studies, adverse events, which commonly include headache, diarrhea, and nausea, occurred in a small percentage of patients. Comparative studies have often been designed to assess the compound against other proton pump inhibitors or older classes of acid-reducing medications (such as histamine-2 receptor antagonists), specifically measuring outcomes like esophageal healing rates and gastric pH elevation.


Use in Special Populations and Acute Care

Research has explored the use of this compound in specific clinical settings, including the prevention of upper gastrointestinal bleeding in critically ill, mechanically ventilated patients. Furthermore, studies have investigated its use in populations with pre-existing conditions, such as those with renal or mild to moderate hepatic impairment, often concluding that dose adjustments were not required in those specific patient groups for its standard indications.

Key Studies & References

  1. ACID: PPIs in Erosive Esophagitis - A Randomized Controlled Trial
  2. NICE Guideline: Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management

Frequently Asked Questions (FAQ)

Common questions about Panref (FAQ)


Q: How quickly does Panref start to work?

Panref is not designed to provide immediate relief for symptoms like heartburn. Official product information indicates that it may take 1 to 4 days of continued use to reach its full effect. This timeframe is consistent with the medicine’s action as a long-lasting acid secretion inhibitor.


Q: Can Panref be taken on an empty stomach?

The administration instructions depend on the form being taken. The delayed-release tablets can be taken with or without food. However, the delayed-release granules for oral suspension are typically recommended to be administered approximately 30 minutes before a meal.


Q: Does Panref cause drowsiness or fatigue?

Official information lists tiredness, asthenia (lack of energy), and fatigue as side effects that have been reported by users. Dizziness is also reported as an uncommon reaction. Patients are generally advised to review all possible side effects with a healthcare professional.


Q: Is Panref safe for older adults?

In clinical trials, older adults (aged 65 and over) experienced similar rates of side effects compared to younger patients. However, official warnings note that long-term or high-dose use in older adults may be associated with a slightly higher risk of bone fracture of the hip, wrist, or spine.


Q: What happens if I forget to take a dose of Panref?

Regarding a missed dose, regulatory-based patient instructions generally describe taking the dose as soon as it is remembered. If it is almost time for the next scheduled dose, instructions usually describe skipping the missed dose and resuming the regular schedule. It is specified that extra doses should not be taken to make up for a missed one.


Q: Can Panref affect my ability to drive?

Because Panref can cause side effects such as dizziness or blurred vision in some people, official information advises caution. Patients experiencing these effects are generally advised to use caution regarding activities that require alertness, such as driving or operating machinery.


Q: What are the typical benefits a patient might expect from Panref?

Panref is intended to decrease the amount of acid produced by the stomach. This reduction in acidity is associated with relieving symptoms like heartburn and difficulty swallowing, as well as promoting the healing of the lining of the esophagus that has been damaged by acid.


Q: Can Panref affect my mood or mental health?

Official adverse event reporting includes the possible occurrence of mood-related side effects. These can include depression (or the aggravation of existing depression) as a common side effect, and rare reports of confusion, disorientation, and hallucination.


Q: Is Panref safe to use during pregnancy?

Official labeling addresses the use of Panref during pregnancy. It states that the medicine is recommended for use only if clearly needed. This reflects the lack of adequate and well-controlled studies specifically conducted in pregnant women.


Q: Can children or teenagers take Panref?

The safety and effectiveness of Panref have been established for the short-term treatment of acid reflux disease (GERD) in pediatric patients 5 years of age and older. The use of Panref in children younger than 5 years old is not established or recommended by official sources.


Q: What official guidance exists if Panref does not appear to be effective?

Official regulatory warnings emphasize that a symptomatic response to treatment with Panref does not completely rule out the presence of a serious underlying stomach condition. For adult patients who have a poor response or an early return of symptoms, the label advises considering additional follow-up and diagnostic testing.


Q: Is there a risk of long-term problems from taking Panref?

Yes, official regulatory documents list potential risks associated with prolonged use, generally defined as one year or longer. These documented risks include an increased chance of bone fracture of the hip, wrist, or spine, and the potential for a severe electrolyte imbalance known as hypomagnesemia (low magnesium levels).


Q: Can I drink alcohol while taking Panref?

Official regulatory documents do not list a direct chemical interaction between Panref and alcohol. However, alcohol consumption can often stimulate the stomach to produce more acid, potentially counteracting the beneficial acid-reducing effect of the medication.


Q: Why does Panref have to be taken at a specific time of day?

The requirement for the oral suspension to be taken approximately 30 minutes before a meal relates to how the drug works in the body. This timing ensures optimal absorption and allows the acid-blocking effect to be maximized when the stomach is naturally stimulated to produce acid by the upcoming meal.


Q: Is there a generic version of Panref available?

Yes, Panref contains the active ingredient pantoprazole. The Food and Drug Administration (FDA) has approved a generic version of this active ingredient, which may be available depending on the specific product and location.


Q: Does Panref cause weight gain or weight loss?

Both weight gain and weight loss have been reported as known but less common effects in studies and post-marketing surveillance. Changes in weight may be related to the drug's effect on appetite or due to the underlying medical condition being treated.


Q: Are there any known severe allergic reactions to Panref?

Yes, the medicine is officially contraindicated (should not be used) in patients with a known hypersensitivity to the drug. Severe allergic reactions reported include anaphylaxis (a severe, life-threatening reaction) and angioedema (swelling beneath the skin).


Q: What are the most serious side effects mentioned in the drug information for Panref?

Official labeling documents several serious but rare adverse reactions. These include severe skin reactions like Stevens-Johnson Syndrome, acute kidney inflammation (Acute Interstitial Nephritis), and severe electrolyte imbalances such as hypomagnesemia (low magnesium levels).


Q: Does Panref interact with herbal supplements?

Official guidance specifically advises not to take St. John’s wort (a common herbal remedy) while using the active ingredient in Panref, as it may reduce the medicine's effectiveness. Official drug labels often lack comprehensive interaction information for all other herbal products.


Q: Can Panref make my skin more sensitive to the sun?

Rare but serious side effects reported include an increased sensitivity to light that can result in a rash when exposed to the sun. Additionally, the medicine may cause or worsen conditions like cutaneous lupus erythematosus, which is often characterized by a rash that worsens with sun exposure.


Q: Do people usually stop taking Panref once their symptoms improve?

For conditions like Erosive Esophagitis, the prescribed course of treatment is typically up to 8 weeks. However, studies indicate that abruptly stopping the medicine after regular use may lead to acid rebound hypersecretion, causing temporary return of dyspeptic symptoms.


Q: Is Panref meant to be used alongside other treatments?

Yes, Panref is sometimes officially indicated for use as part of combination treatment regimens. These uses include managing Pathological Hypersecretory Conditions (like Zollinger-Ellison Syndrome) and being used in combination to treat certain bacterial infections.


Q: Are there any known interactions between Panref and common over-the-counter pain relievers?

When checking official drug interaction resources, there are generally no known interactions found between Panref and very common OTC pain relievers such as acetaminophen. However, this does not cover all pain relievers, and patients should always disclose all medications they take.


Q: Is Panref safe for people with kidney disease?

Yes, official documents indicate that the medicine can be used in patients with severe kidney problems. Specifically, no dose adjustment is required for those with severe renal impairment or those with End-Stage Renal Disease (ESRD).

How should Panref be stored and disposed of?

How to Store and Dispose of Panref?

The storage and disposal of Panref (Pantoprazole delayed-release tablets) must follow official regulatory guidelines to maintain its stability and ensure safety.

Storage Conditions

Panref tablets must be stored at Controlled Room Temperature, specifically between 20^circ and 25 C (68^circ to 77 F), to preserve the integrity of the delayed-release coating. The medicine must be kept in its original container, tightly closed, and protected from excess heat and moisture. It is a mandatory child-safety requirement that Panref is always kept out of the sight and reach of children.

Disposal Instructions

To dispose of unused or expired Panref, do not flush the tablets down the toilet or throw them in the regular household trash unless specifically mixed with an undesirable substance. The product must be discarded in accordance with local requirements, with the preferred method being a designated drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Panref found in:

A-Z Index: